AIDS
Conditions
Interventions
Experimental group:Intravenous esketamine 0.15 mg/kg + sufentanil 2µg/kg + esketamine 0.5mg/kg + ondansetron 8mg + 0.9% sodium chloride solution was mixed to 100mL for postoperative analgesia
Control group:sufentanil 2µg/kg+ondansetron 8mg +0.9% sodium chloride solution was mixed to 100mL for postoperative analgesia
Sponsors
Shenzhen Third People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Aged 18-60 years old, ASA I-II, BMI 18~30kg/m2. Diagnosed with human immunodeficiency virus (HIV) infection and AIDS before surgery, and was treated with high-activity-anti-retroviral-therapy (HAART) for more than 6 months, and the condition was stable, and anal fistula surgery was planned.
Exclusion criteria
Exclusion criteria: (1) Combined with severe anemia (Hb3s); APTT extension >10s; PLT<80*10^9/L (2) Patients who are currently being treated with opioids or other analgesics, or who have psychiatric disorders that affect pain scores, who use psychiatric drugs and are allergic to the components of the drugs used in this study, (3) Neuraxial anesthesia contraindications are also excluded, (4) Patients with contraindications to esketamine, such as those at serious risk of elevated blood pressure or intracranial pressure, patients with poorly controlled or untreated hypertension (arterial hypertension, resting systolic blood pressure/ Diastolic blood pressure greater than 180/100 mmHg); untreated or undertreated hyperthyroidism (hyperthyroidism)patients, etc. (see esketamine drug instructions for details). (5) Unable to complete the preoperative and postoperative evaluations or the treating physician is deemed unsuitable to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IL-6;TNF-a; | — |
Secondary
| Measure | Time frame |
|---|---|
| visual analogue scale, VAS;Ramsay score;Patient satisfaction scores; | — |
Countries
China
Contacts
Public ContactWu Qiang
Shenzhen Third People's Hospital
Outcome results
None listed